Ongoing Uncertainties And Downgrades Will Shape Efficiency Efforts Ahead

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

09 Feb 25

Updated

27 Nov 25

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-66.2%

7D

3.1%

Loading

1Y

-66.2%

7D

3.1%

You can edit this narrative until Nov 28 5:10 AM. Then, changes will post as Updates.

Author's Valuation

€34.6226.0% undervalued

AnalystConsensusTarget Fair Value

Shared on 27 Nov 25

GXI: Long-Term Sector Demand Will Support Confidence After Recent Leadership Change

Gerresheimer's analyst price targets have been significantly reduced recently, with analysts citing ongoing uncertainties and diminished near-term visibility as key factors for the downward revision. Previous targets exceeded €50, but new values are now in the €23 to €46 range.

Shared on 10 Nov 25

Fair value Decreased 8.50%

GXI: Confidence Will Remain Despite Current Uncertainties And Leadership Transition

Gerresheimer's analyst fair value target has been revised downward from €37.84 to €34.62. This change reflects recent broad cuts in price targets by analysts, who cite low visibility and ongoing uncertainties around the company's outlook.

Shared on 27 Oct 25

Fair value Decreased 33%

Gerresheimer's analyst price target has been significantly reduced from €56.36 to €37.84. Analysts cite heightened uncertainties, reduced growth expectations, and a lack of near-term catalysts as reasons for this more cautious outlook.

Shared on 13 Oct 25

Fair value Decreased 12%

Analysts have lowered their price target for Gerresheimer from €63.72 to €56.36. They cite more cautious expectations for revenue growth and profitability going forward.

Shared on 23 Sep 25

Fair value Decreased 4.67%

The downward revision in Gerresheimer’s price target reflects recent declines in both net profit margin and consensus revenue growth forecasts, resulting in a reduced fair value estimate from €66.84 to €63.72. What's in the News Wolf Lehmann appointed as incoming CFO, succeeding Dr. Bernd Metzner; Lehmann brings nearly 30 years of international finance and management experience.

Shared on 01 May 25

Fair value Decreased 28%

Shared on 23 Apr 25

Fair value Decreased 2.03%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

Fair value Decreased 5.26%

AnalystConsensusTarget has increased discount rate from 6.3% to 7.4%.

Shared on 09 Apr 25

Fair value Decreased 1.03%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

Fair value Decreased 1.29%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

Fair value Increased 50%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Decreased 4.13%

AnalystConsensusTarget Fair Value

€34.62

26.0% undervalued

Future estimation in

% p.a.

0

Decrease

Increase

Current revenue growth rate

5.53%

Life Sciences revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

9.98%

Calculation

€117.89m

Earnings '28

x

13.28x

PE Ratio '28

=

€1.57b

Market Cap '28

€1.57b

Market Cap '28

/

34.54m

No. shares '28

=

€45.34

Share Price '28

€45.34 Share Price '28

Discounted to 2025 @ 9.98% p.a.

=

€34.08

Fair Value '25